We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Intelligent Ultrasound Group Plc | LSE:IUG | London | Ordinary Share | GB00BN791Q39 | ORD 1P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.00 | 0.00% | 12.875 | 0.00 | 00:00:00 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| - |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| - | O | 0 | 12.875 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 19/2/2025 | 07:00 | UK RNS | AIM Cancellation - Intelligent Ultrasound Group plc |
| 18/2/2025 | 16:43 | UK RNS | Intelligent Ultrasound Group PLC Holding(s) in Company |
| 18/2/2025 | 14:10 | UK RNS | Intelligent Ultrasound Group PLC Holding(s) in Company |
| 18/2/2025 | 07:30 | UK RNS | AIM Suspension - Intelligent Ultrasound Group plc |
| 18/2/2025 | 07:29 | ALNC |  *Intelligent Ultrasound shares suspended as takeover by Surgical Science.. |
| 18/2/2025 | 07:12 | UK RNS | Intelligent Ultrasound Group PLC Scheme of Arrangement Becomes Effective |
| 14/2/2025 | 12:04 | UK RNS | Intelligent Ultrasound Group PLC COURT SANCTION OF SCHEME OF ARRANGEMENT |
| 14/2/2025 | 10:58 | UK RNS | Cavendish Securities PLC Form 8.5 (EPT/NON-RI) |
| 13/2/2025 | 10:04 | UK RNS | Cavendish Securities PLC Form 8.5 (EPT/NON-RI) |
| 11/2/2025 | 18:00 | UK RNS | FTSE Russell Intelligent Ultrasound Group |
Intelligent Ultrasound (IUG) Share Charts1 Year Intelligent Ultrasound Chart |
|
1 Month Intelligent Ultrasound Chart |
Intraday Intelligent Ultrasound Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 04/3/2025 | 15:22 | Intelligent Ultrasound. Clinical AI software | 602 |
| 26/4/2023 | 08:27 | Intelligent Ultrasound Group | 113 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|
| Top Posts |
|---|
Posted at 04/3/2025 15:22 by maddox Money is in at X-O.Best wishes to IUG and shareholders. Regards, Maddox |
Posted at 31/1/2025 07:57 by bamboo2 I have not noticed text of this type before. Is this normal or is the co. worried that they don't have a convincing majority in favour?================== It is important that, for the Court Meeting in particular, as many votes as possible are cast so that the Court may be satisfied that there is a fair and reasonable representation of the opinion of Scheme Shareholders. Intelligent Ultrasound Shareholders are therefore strongly encouraged to submit proxy appointments and instructions for the Court Meeting and the General Meeting using any of the methods set out in the circular dated 15 January 2025 relating to the recommended cash offer by Surgical Science Sweden AB to acquire the entire issued and to be issued share capital of Intelligent Ultrasound (the "Scheme Document") as soon as possible and, in any event, by no later than 10.00 a.m. on 4 February 2025 in the case of the Court Meeting and by no later than 10.15 a.m. on 4 February 2025 in the case of the General Meeting (or, in the case of any adjournment, not later than 48 hours (excluding any part of such 48-hour period falling on a non-Business Day) before the fixed time for the holding of the adjourned meeting). Intelligent Ultrasound Shareholders are also strongly encouraged to appoint "the Chair of the meeting" as their proxy. Intelligent Ultrasound Shareholders entitled to attend and vote at the Court Meeting and General Meeting may appoint a proxy online by using the Link Investor Centre app or at hxxps://investorcent |
Posted at 22/1/2025 17:43 by gsbmba99 Just for the fun of it, I checked the FDA's 510(k) database. As it happens, a new version of Voluson Expert was approved in late December. The filing date was 24 July or 6 days after the proposed sale of the AI business was announced. This new 510(k) features a new SonoLyst product - 1st Trimester - in addition to 2nd Trimester. I wonder if I am reading too much into the fact that the filing wasn't made until after IUG agreed to sell them the Clinical AI business? |
Posted at 15/1/2025 07:12 by bamboo2 Event Expected time/datePublication of this Announcement 15 January 2025 Publication of the Scheme Document 15 January 2025 Latest time for lodging BLUE Forms of Proxy for Court Meeting 10.00 a.m. on 4 February 2025 Latest time for lodging YELLOW Forms of Proxy for General Meeting 10.15 a.m. on 4 February 2025 Voting Record Time for Court Meeting and General Meeting 6.00 p.m. on 4 February 2025 Court Meeting 10.00 a.m. on 6 February 2025 General Meeting 10.15 a.m. on 6 February 2025 The following dates are indicative only and are subject to change Scheme Court Hearing to sanction the Scheme 14 February 2025 Last day of dealings in, and for registration of transfers of, Intelligent Ultrasound Shares 17 February 2025 Scheme Record Time 6.00 p.m. on 17 February 2025 Disablement of CREST in respect of Intelligent Ultrasound Shares 6.00 p.m. on 17 February 2025 Effective Date of the Scheme 18 February 2025 Suspension of admission to trading of, and dealings in, Intelligent Ultrasound Shares before markets open on 18 February 2025 Cancellation of admission of trading on AIM of Intelligent Ultrasound Shares 8.00 a.m. on 19 February 2025 Despatch of cheques, despatch of electronic payments and crediting of CREST accounts for cash consideration under the Scheme within 14 days of the Effective Date Long Stop Date 30 June 2025 Suspension, Cancellation of admission to trading on AIM of Intelligent Ultrasound Shares and Re-Registration It is expected that dealings in Intelligent Ultrasound Shares will be suspended at 7.30 a.m. London time on the day which is two Business Days after the Scheme Court Hearing. Application is being made to the London Stock Exchange for the cancellation of admission to trading of the Intelligent Ultrasound Shares on AIM, to take effect shortly following the Effective Date. On the Effective Date, share certificates in respect of Intelligent Ultrasound Shares shall cease to be valid and entitlements to Intelligent Ultrasound Shares held within the CREST system shall be cancelled. It is also intended that, as soon as possible after the Effective Date and after its shares cease to be traded on AIM, Intelligent Ultrasound will be re-registered as a private limited company under the relevant provisions of the Companies Act. |
Posted at 19/12/2024 17:07 by petomi The Chair's comments when the Clinical AI sale completed back in the autumn(1 Oct RNS) look a bit hollow now:"The remaining simulation business has tremendous potential with an excellent product range particularly in new areas such as needling. Our mission is to make ultrasound easier to learn and simpler to teach, as we aim to support the rising demand for sonographers worldwide. Over the last six weeks we have been engaged in a comprehensive review of the remaining Simulation Business that has involved evaluating the potential of expanding both our medical simulation product range, as well as our sales operations in both reach and scale. On completion of the capital reduction we look forward to communicating the details of the Company's plans." Yet they are now effectively selling the simulation business for buttons. I doubt whether a competing bid will emerge since presumably it has been properly exposed to the likely limited number of potential buyers but we shall see. It doesn't look as if the advisers have covered themselves in glory. Buyer's share price up 2.5% rubs it in. [Edited: I previously said 11% but graph on their website was misleading - their share price rose 2.5% to close at SEK158.3 yesterday. With mkt cap of SEK8bn, c£600m, the increase was nearly £15m, ie their market thought this relatively small purchase was a great deal....for them.] I will look at the scheme circular in detail. |
Posted at 19/12/2024 08:47 by route1 I understand this RNS, which is an offer to buy/acquire the simulation business, but there seems to be no mention of the capital return which according to a previous RNSwas due to be paid 'sometime in December'.So will the capital return be paid to shareholders this month once the amount per share is confirmed, or will it be included in the final acquisition price? |
Posted at 12/12/2024 13:37 by bmcollins I was hoping for some hard news by now, at this rate our IUG Christmas present could be a Hogmany one or even later than that ! |
Posted at 01/10/2024 23:38 by 40 fathoms Net Cash @40 million (interest income at @140k per month)Market Cap @34 million Annual Revenue from Simulation Business @10 million Gross Margins from Simulation Business @65% Simulation Business essentially at cash flow breakeven. So much for the Efficient-market hypothesis. The simulation business and 6 million in net cash is excluded from the current share price. |
Posted at 18/7/2024 08:13 by bamboo2 Intelligent Ultrasound Group PLC Proposed sale of Clinical AI Business for £40.5m 18/07/2024 8:19amProposed sale of the Clinical AI Business to GE HealthCare for £40.5 million Notice of General Meeting Trading update Intelligent Ultrasound Group plc (AIM: IUG), the ultrasound AI software and simulation company, is pleased to announce it has entered into a conditional sale and purchase agreement for the sale of its Clinical AI business (Intelligent Ultrasound Limited and certain other clinical AI related assets) to GE HealthCare for an enterprise value of £40.5 million on a cash free/debt free basis (the "Proposed Transaction"). The Proposed Transaction excludes the NeedleTrainer and NeedleTrainer Plus products which will remain within the Company along with the Simulation Business. Transaction highlights: · Sale of the Clinical AI Business to GE HealthCare agreed for an enterprise value of £40.5 million. · Disposal excludes the NeedleTrainer/Traine · The consideration represents a implied value of 12.4p per Ordinary Share on current issued share capital and a premium of 70.9 per cent to the Ordinary Share price on 17 July 2024 and a premium of 30.9 per cent to the volume weighted share price for the last 12 months. The Proposed Transaction also values the Clinical AI Business at 33.8 times full year 2023 revenues of that business. · The transaction is subject to shareholder approval under AIM Rule 15, as well as confirmations from the Competition and Markets Authority under the Enterprise Act, and the Investment Security Unit under the National Security and Investment Act, that they do not oppose the transaction (the "Regulatory Consents") · It is the Board's intention to make a material return of capital following a review of the growth potential and capital requirements of the post-transaction business and taking legal and tax advice on structure of a return. An announcement detailing the proposed use of funds and future strategic direction for the post-transaction business is expected to be made by the time of completion of the Proposed Transaction, which, dependent on the timing of the Regulatory Consents, is expected to be in September/October this year. · The Company has received irrevocable undertakings and letters of intent from certain Shareholders (including the Directors) representing approximately 54.6 per cent of the Ordinary Share capital to vote in favour of the Resolution. Further details of the Proposed Transaction are set out below. The Board of Intelligent Ultrasound is committed in its duty to provide value to shareholders and therefore has continually sought to evaluate strategic options available to the Company to do so. For some time the Board has been considering how best to optimise and accelerate the growth of the Clinical AI Business. The Company acquired its Clinical AI Business in October 2017 through its purchase of Intelligent Ultrasound Limited, a University of Oxford spin-out company, for £3.6 million and has committed capital to it to date of approximately £12.2 million (as adjusted to remove NeedleTrainer development costs but including the £3.6 million initial purchase price). Whilst the Board takes great pride in the development capability that has been created in the Clinical AI Business, to date, the growth of the ScanNav related AI revenue streams has been slower than was originally forecast. Furthermore, the Company has not yet reached commercial terms with GE HealthCare for all the future products on its women's health roadmap. Materially growing the value of the Clinical AI Business therefore relies on also developing products outside the existing relationship with GE HealthCare, including ScanNav FetalCheck (for gestational age estimation) and ScanNav Liver (to support hepatologists diagnose and monitor MASH and MAFLD). Although the Company has supportive Shareholders, it has never been able to achieve the up-front funding levels of its competitors and, with financing conditions for small growth companies uncertain, the probable additional investment required must be balanced against ongoing execution risk and the Company's goal of reaching profitability on current cash resources. When assessing the value of the Clinical AI Business, the Board has taken into account the following elements: · the current and expected revenues from royalties paid by GE HealthCare for the use of the ScanNav Assist ultrasound AI software under the Women's Healthcare Licence; · the current and potential value of the ScanNav Anatomy PNB product; · the potential value of the ScanNav FetalCheck gestational age product; and · the value of the Group's future products such as ScanNav Liver, as well as the value of the broader technology and capabilities of the business and its team. The Board considers that GE HealthCare's offer represents a fair net present value for these revenue streams, taking into account the current value accorded to the Company by the capital markets, the expected execution risk and potential dilution required to make the requisite investment in the Clinical AI Business. Notice of General Meeting The Company will shortly post a Circular to Shareholders regarding the Proposed Transaction, which sets out a Notice of General Meeting, and a Form of Proxy for the proposed resolutions. These documents will also be available on the Company's website. Current Trading and Outlook: The Company today also issues a trading update for the period ended 30 June 2024. Unaudited revenue in the first half of the year declined by 18% to £5.1 million (H1 2023: £6.1 million), with simulation sales (excluding NeedleTrainer) down 34% to £3.5 million (H1 2023: £5.3 million). This results from a decline in the UK and North American markets · The decline in UK sales was expected, due to previously flagged NHS budget pressure, reducing sales almost 60% to £0.8 million (H1 2023: £1.9 million) · However, the 23% decline in North America sales to £2.2 million (H1 2023: £2.8 million) was not anticipated, with nearly £0.8 million of expected sales held in delivery backlog or last-minute purchase order delays. Positives in the first half were: · ROW reseller sales growing over 30% to £1.6 million (H1 2023: £1.1 million); and · Clinical AI related revenue doubling to £1.5 million (2023: £0.7 million) of which NeedleTrainer increased to £1.0 million (H1 2023: £0.5 million). · Cash overheads in the business were £4.3 million (H1 2023: £4.9 million) and reflect a number of cost saving across the Group. · Cash burn reduced significantly in H1 2024 to £2.0 million (H1 2023: £3.8 million) leaving cash as at 30 June of £1.0 million (31 December 2023: £3.0 million). Irrevocable undertakings Completion is conditional upon, inter alia, the passing of the Resolution by Shareholders at the General Meeting. The Company has received irrevocable voting undertakings and letters of intent to vote in favour of the Resolution from certain Shareholders (including the Directors) representing approximately 54.6 per cent of the Ordinary Share capital. Amendment to the M&A Bonus arrangement The Remuneration Committee proposes to make the following changes to the M&A Bonus that it put in place for executives in December 2020 following consultation with its major shareholders: · Thresholds to be adjusted in line with the Company's benchmark index, the FTSE AIM All Share. · The threshold will be determined by gross total shareholder return per share ie including all gross amounts returned to shareholders. o Following Completion, Nick Sleep, the Chief Technology Officer, will transfer with the Clinical AI Business and leave the M&A Bonus. If the minimum threshold is reached the minimum bonus payment will be 50% of annual salary. The participation of the Executive Directors, Stuart Gall and Helen Jones in the M&A Bonus scheme constitutes a 'related party transaction' under the AIM Rules. The independent Directors (being the Directors other than Stuart Gall and Helen Jones) consider (having consulted with the Company's nominated adviser, Cavendish) that the terms of the M&A Bonus and the proposed amendment are fair and reasonable insofar as the Company's Shareholders are concerned. Commenting on the Proposed Transaction, Riccardo Pigliucci, Chairman of Intelligent Ultrasound said: "At Intelligent Ultrasound Plc we have spent the last seven years successfully creating first-to-market AI products and have built a strong capability in real-time automated ultrasound image analysis. When GE HealthCare offered us £40.5 million to acquire our Clinical AI Business, we were pleased that our achievements were recognised but it presented us with the very difficult decision to exit the main market we had chosen for our future growth. To date, the growth of our current ScanNav related clinical AI revenues has been slower than we had originally expected and, most importantly, insufficient to fund the developments needed to materially increase the value of the Clinical AI Business. We have had to recognise that developing products such as ScanNav FetalCheck for gestational age estimation and ScanNav Liver is costly and would require the sort of funding levels that are outside the Group's current cash resources or capital raise capabilities. The Board has therefore concluded that accepting GE HealthCare's offer is in the best interest of the Company's shareholders and represents a fair net present value for these potential future revenue streams and recommends it to shareholders for their approval. The remaining Simulation Business, which will be boosted by the inclusion of the NeedleTrainer range previously reported in our Clinical AI business, is a solid one and the Board will use the time between signing and completion of this Proposed Transaction to conduct a comprehensive review of the business. It is the Board's intention to make a material return of capital following a review of the growth potential and capital requirements of the post-transaction business and taking legal and tax advice on structure of a return. An announcement detailing the proposed use of funds and strategic direction for the Company is expected to be made by the time the Proposed Transaction completes." |
Posted at 14/7/2024 10:34 by bmcollins @40fThanks for this I have just listened to it, very positive. What intrigues me most about our current position is why have healthcare professionals, Dr's etc not been buying IUG stock ? I recall that when Glaxo became a favourite stock on Nasdaq because of the potential of Zantac, the great bulk of the U.S. demand for the stock, in the first instance, came from Dr's & other clinicians who realised how effective it was for stomach ulcers. That was 40 odd years ago & now of course Zantac is a dirty word for GSK. Even a modest number of health professionals buying IUG, given its illiquidity, would have a very positive result on the share price Perhaps this could happen as more people use our facility on their GE machines, I'd like to think so but am not holding my breath ! |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
